Effect of Remazolam Besylate Combined With Remifentanil Analgesic Sedation on the Prognosis of Patients With Sepsis
Key facts
- Who runs it
- First Affiliated Hospital of Ningbo University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 100 people, planned
- Started
- 1 Jan 2025
- Planned end
- 31 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Midazolam
- Remazolam besylate
- Record updated
- 10 April 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Mechanical ventilation patients with sepsis who are expected to stay in ICU for ≥48h
- The condition was allowed to remain in shallow sedation (RASS-2 ~0)
- Obtain informed consent from patients or family members
Who cannot take part
- General anesthesia surgery within 48 hours
- Participate in other exploratory clinical trials within 6 months prior to screening
- Severe, pre-existing parenchymatous liver disease with clinically significant portal hypertension, Child-Pugh grade C cirrhosis or acute liver failure
- Patients with acute and chronic renal insufficiency requiring dialysis treatment
- Patients with a history of alcohol or drug abuse
- Any condition that prevents the correct assessment of cognitive function, such as speech and sensory disorders or mental disorders (language difficulties or organic mental dysfunction)
- Failure to obtain informed consent or authorization
- Known or suspected allergy to the study drug
- pregnancy or breastfeeding
- Severe craniocerebral injury, brain tumor, increased intracranial pressure, cerebrovascular accident, coma, epileptic status, etc. 6 Medical Ethics Committee of the First Affiliated Hospital of Ningbo University
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sepsis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In this study, midazolam was used as a control to investigate the effect of remazolam besylate combined with remifentanil on analgesia and sedation in patients with mechanical ventilation of sepsis on the prognosis of patients, and to provide evidence for the safe application of remazolam besylate in patients with sepsis.
The 2 groups in the trial
- MidazolamExisting treatment, for comparison
- Remazolam benzenesulfonateExisting treatment, for comparison
Treatment: Remazolam besylate
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT06731088, who can take part
- Record updated
- 10 April 2025